Ion Exchange Resins. Unique Solutions to Formulation Problems

Similar documents
REVISION OF MONOGRAPH ON TABLETS. Tablets

ENHANCEMENT OF SOLUBILITY OF BICALUTAMIDE DRUG USING SOLID DISPERSION TECHNIQUE

Biopharmaceutics Dosage form factors influencing bioavailability Lec:5

1. Gastric Emptying Time Anatomically, a swallowed drug rapidly reaches the stomach. Eventually, the stomach empties its content in the small

Innovations in Design: NIA-West. Missy Lowery, MSc Head of Integrated Marketing Capsugel, now a Lonza company 11/13/2017

A FACTORIAL STUDY ON THE ENHANCEMENT OF DISSOLUTION RATE OF KETOPROFEN BY SOLID DISPERSION IN COMBINED CARRIERS

Direct Compression. With the right ingredients it s a simple, cost-effective manufacturing process

LYCOAT. New solutions for Film Coating from Roquette. LYCOAT for quicker quality coating

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

CHAPTER-I DRUG CHARACTERIZATION & DOSAGE FORMS

USP Chewable Gels Monographs

Determination of bioavailability

Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy

Define the terms biopharmaceutics and bioavailability.

2- Minimum toxic concentration (MTC): The drug concentration needed to just produce a toxic effect.

PHARMACEUTICS I صيدالنيات 1 UNIT 1 INTRODUCTION

7. SUMMARY, CONCLUSION AND RECOMMENDATIONS

In-Vitro Bioequivalence Studies for Oral Solid Dose products using the Morphologi G3-ID

Fang Liu University of Hertfordshire

FORMULATION AND CHARACTERIZATION OF TELMISATAN SOLID DISPERSIONS

Dow Wolff Cellulosics. Using ingenuity and savvy. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow

FORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels

Folic Acid in Human Nutrition

Formulation and Evaluation

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

Documents Regarding Drug Abuse Assessments

Student Practical Guide (1) Milk of Magnesia

Industrial Pharmacy (3) Solutions as a dosage form. DR.Saad.M.YACOUB

STARCH Proven and Trusted Excipient for Performance and Versatility EXCIPIENTS. Effective and economical disintegrant

Easy, fast and reliable!

Draft Guideline on Pharmaceutical Development of Medicines for Paediatric Use. C. Nopitsch-Mai London 1

PHAR 7632 Chapter 7. Table Market and Share of Pharmaceuticals by ROA Data from Viswanathan, 2004

Is the science that study relation of physicochemical properties of drug, dosage form, & route of administration on rate and extent of drug

Comparative Evaluation of Enteric Film Coatings Applied in Organic Solvents

Easy, fast and reliable!

Advantages and Limitations of In Vivo Predictive Dissolution (IPD) Systems

REGULATORY PERSPECTIVE. Dr. Raghunandan H V Associate Professor JSSCP, JSSU, Mysore

LAB.2. Tablet Production Methods

ANIMAL HEALTH DIVISION. Technologies & Services

SPS Pharma: Who we are?

Fundamentals of Pharmacology for Veterinary Technicians Chapter 4

SCIENTIFIC DISCUSSION

New formulas for successful drug delivery Hot-melt extrusion for enhanced solubility and bioavailability

Biopharmaceutics. Lec: 4

High-Absorbable Ferric Pyrophosphate for Iron Supplement. Ferrsorb

SCIENTIFIC DISCUSSION. Lopinavir and Ritonavir 200 mg/50 mg Tablets * Name of the Finished Pharmaceutical Product:

Advantages and Limitations of In Vivo Predictive Dissolution (IPD) Systems

CONTENTS PAGE. Please note: Preface Matrix system Selection of METOLOSE grades Specifications

The professionals choice.

Tablet is a major category of solid dosage forms which are widely used worldwide. Extensive information is required to prepare tablets with good

D9G : Oro-Mucosal Dosage Forms Development Background Paper

Lipid Based Matrices as Colonic Drug Delivery System for Diflunisal (In-vitro, In-vivo study)

The Pharmacy Board of Australia s

Journal of Pharmaceutical and Scientific Innovation

VIVAPHARM PVP/VA. Copovidone, Ph.Eur. USP/NF, JPE, E. The Ultimate Tablet Binder for All Processing Technologies

Rationale for dissolution testing. Dissolution testing of nonconventional. Dissolution for IVIVC. Practicality of testing. Apparatus 3 BP 2011

Novel drug delivery system. Nanos-in-Micros

innovative products. faster to market. reliably supplied.

SCIENTIFIC DISCUSSION

III. United States Patent (19) Carlsson et al. 11 Patent Number: 5, Date of Patent: Apr. 30, 1996

skim milk as carrier by kneading method. They were evaluated for percentage yield, drug content, FT-IR

SCIENTIFIC DISCUSSION

CONSIDERATION OF THE END USER AND THE LIMITATIONS DURING THE ORAL ADMINISTRATION DRUG DESIGN: CHALLENGE IN DIFFERENT AGE GROUPS

DRUG PRODUCT PERFORMANCE: CONSIDERATIONS FOR INTERCHANGEABILITY OF MULTISOURCE DRUG SUBSTANCES AND DRUG PRODUCTS

Children Orosensory Perception and Taste Masking of Paediatric Formulations. Paolo Gatti, PhD Research Fellow and Manager Formulation

SCIENTIFIC DISCUSSION

Formulation Development of Aceclofenac Tablets Employing Starch Phosphate -A New Modified Starch

DESIGN AND DEVELOPMENT OF COLON TARGETED DRUG DELIVERY SYSTEM OF 5 FLUORURACIL & METRONIDAZOLE

Bioavailability enhancement of poorly soluble APIs. Enhanced solubilization out of solid glassy solutions prepared by Hot-Melt Extrusion

DISCIPLINE RECORD/ COURSE / SEMINAR DESCRIPTION

Unigel TM Case Study: Extending Soft Gelatin Capsule Benefits to Novel Fixed Dose Combinations

SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS. Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical

Formulation factors affecting acceptability of oral medicines in children

Completion of the development of a formulation: Requirements for compliance check vs. requirements for Marketing Authorisation

Opadry Enteric. Application Data. Drug Release from Acrylic-Based Opadry Enteric (94 Series) Coated Tablets INTRODUCTION MATERIALS AND METHODS

STARCHES FOR COSMETIC INDUSTRIES CORN PO4 PH B AND RICE NS

Research Paper Taste Masking of Topiramate by Newer Range of Ion-Exchange Resin

Kollicoat Smartseal 30 D Active Protection

The unlocked synergy of DFE Pharma MCC

Pharmaceutical Preparation For Internal Use

Osnove farmakokinetike. Aleš Mrhar. Prirejeno po. A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne,

Global College of Pharmacy, Kahnpur Khui, Tehsil Anandpur Sahib, Distt.- Ropar, Punjab, India

Comparison - Aqueous vs. Solvent based Ethylcellulose Films. H.S. Hall, K.D. Lillie & R.E. Pondell

Suppository Chapter Content

Table 1. Coating Parameters

Research Envisaged and Selection of Drug Candidate

EUDRATEC GRS. Your floating solution for an improved absorption in the stomach.

Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution)

EVALUATION OF EFFERVESCENT FLOATING TABLETS. 6.7 Mathematical model fitting of obtained drug release data

INFORMATION TOPIC: II-5 OR DEMONSTRATION: II-5. DOSAGE, MEASUREMENTS, AND DRUG FORMS (Lesson Title) OBJECTIVES THE STUDENT WILL BE ABLE TO:

International Journal of Innovative Pharmaceutical Sciences and Research

Formulation and evaluation of fast dissolving tablet of aceclofenac

ACUMER 4161 Phosphinopolycarboxylic Acid Scale Inhibitor and Dispersant

DRY SYRUPS SWAPNA.M. Ist semester DEPARTMENT OF PHARMACEUTICS UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES KAKATIYA UNIVERSITY, WARANGAL SEMINAR BY

Critical material properties for the design of robust drug products : excipient functionality related characteristics

Research Article. Formulation, evaluation and stability study of sennoside A & B capsule

SCIENTIFIC DISCUSSION

Antacid therapy: Antacids side effects:

The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts.

Journal of Chemical and Pharmaceutical Research

Transcription:

Ion Exchange Resins Unique Solutions to Formulation Problems Lyn Hughes Some of the common problems faced by formulators and how using ion exchange resins may be able to solve them are discussed. PHOTODISC, INC. Lyn Hughes, PhD, is a global technical service manager for healthcare in the Process Solutions Groups at Rohm and Haas Company, Spring House Technical Center, 77 Norristown Road, Spring House, PA 19477-94, tel. 15.641.739, fax 15.619.168, lhughes@ rohmhaas.com. Ion exchange resins have been used to help formulate pharmaceuticals since the late 195s. During that time, they have proven to be safe and effective excipients and are now used in many commercial formulations throughout the world. This article will look at some of the common problems faced by formulators and how using ion exchange resins may be able to solve them. Ion exchange resins are insoluble polymers that contain acidic or basic functional groups and have the ability to exchange counter-ions within aqueous solutions surrounding them. The equation in Figure 1 shows a representative reaction when drugs are loaded onto or released from the resins. A drug ion and an inorganic ion are exchanged. The reaction is an equilibrium, the position of which will depend on many factors such as salt concentration in the aqueous phase. This property enables drugs to be loaded onto resins (forming drug resinates) and then released in vivo by the salts present in gastro-intestinal Pharmaceutical Technology EXCIPIENTS & SOLID DOSAGE FORMS 4 www.pharmtech.com

Excipients & Solid Dosage Forms N+(R) CI - + API-CO Na 3 N+(R) 3 AP-CO - NaCI Figure 1: The equation shows a representative reaction when drugs are loaded onto or released from the resins. fluids. The resinates possess physical properties similar to those of the resin. These two properties drug release and physical properties can be manipulated to create many variations of use to the formulator. Stability. The drug resinate is frequently more stable than the original drug. This tendency is exemplified by the stabilization of vitamin B 1 in the oldest pharmaceutical resinate application. Vitamin B 1 has a shelf life of only a few months, but the resinate is stable for more than two years. This technology is still used commercially today, more than 4 years after it was first introduced. Another example is nicotine. Nicotine discolors quickly when exposed to air and light but the resinate (used in nicotine chewing gums and lozenges) is much more stable. Poor dissolution. Many of today s drugs are poorly soluble because of slow dissolution and/or low solubility. The rate of release of poorly soluble, ionizable drugs from a resinate can be much quicker than the rate of dissolution of the pure drug. An excellent example is that of indomethacin, which is only soluble up to 6 ppm in simulated gastric fluid but is released very quickly from a resinate (see Figure ). Stirring an excess of indomethacin in simulated gastric fluid for three days achieved a concentration of only 1 ppm, whereas exposing a resinate of indomethacin to the same fluid yielded a saturated solution within 3 minutes. Using micronization to increase the rate of dissolution can be problematic because the technique frequently requires specialized equipment and often involves a problem with agglomeration of the fine particles after grinding. The grinding process also can lead to melting and conversion to other crystal forms. These problems can be eliminated by the use of ion exchange resins. Deliquescence. Deliquescence is the property of a solid such that it absorbs so much water that it dissolves in the water it absorbs. Although this is not a common problem, it has been very difficult to solve and requires the use of specialized equipment or careful scheduling of production during dry seasons. However, the resinate of a deliquescent drug is not deliquescent, permitting its formulation into typical dosage forms in standard equipment. Figure 3 shows the results of tests conducted on resinates of sodium, a well-known highly deliquescent drug. Even under such severe conditions, the resinates remain solid. In Pharmaceutical Technology EXCIPIENTS & SOLID DOSAGE FORMS 4 www.pharmtech.com +

fact, the amount of water absorbed decreases as the amount of in the resin increases. Under typical ambient conditions, the resin remains free-flowing even if water is absorbed. Polymorphism. Unlike deliquescence, polymorphism is a very common problem in the pharmaceutical industry, and huge sums of money are spent trying to identify polymorphs and making stable, suitably soluble Concentration (mg/l) 7 6 5 4 3 Dissolution/release of indomethacin in simulated gastric fluid Indomethacin resinate Micronized Indomethacin 1 1 3 4 5 6 7 8 Time (hours) Figure : The graph shows the level of concentration versus the time it takes for indomethacin to dissolve in simulated gastric fluid. forms. Failure to resolve such problems can result in significant stability problems for the final dosage form. Ion exchange resins present a unique way to solve the problem. A drug resinate is an amorphous solid that cannot crystallize or even form hydrates. In addition, the release of the drug from the resinate is independent of the crystal form that was used to make it. Consequently, the use of resinates can eliminate any problems with polymorphism. Figure 4 shows release dissolution test data on lansoprazole and its resinates. These data clearly demonstrate that although the original crystal forms of the drug had very different dissolution rates, the release rates from the resinates were all the same. Physical state. Some drug substances are liquids or difficult-tohandle solids. Because the physical properties of the resinates are similar to those of the resin and not the drug, the resinates of these troublesome drugs are free-flowing solids. A very well established example of this is the nicotine resinate used in nicotine chewing gums and lozenges. Nicotine is a liquid, but the resinate is a stable, free-flowing solid. Tablet disintegration. Some ion exchange resins will swell significantly when immersed in water. This property has led to their use as very effective tablet disintegrants. It is usually necessary to use only a few percent of the tablet weight to get complete disintegration within several minutes. Taste. Because resinates are insoluble in water, they have no taste. This makes them excellent candidates for masking foul-tasting drugs. As long as the rate of release of the drug on contact with saliva is sufficiently slow (and it frequently is), this technology can work extremely well. It is equally applicable to liquid formulations (suspensions) and mouth-dissolving Pharmaceutical Technology EXCIPIENTS & SOLID DOSAGE FORMS 4 3

Excipients & Solid Dosage Forms tablets. It is particularly effective in liquid formulations because the resinate will represent the thermodynamically stable form so that leaching of the drug into the aqueous phase will not occur. There are several examples of the use of this technology in the marketplace, including a liquid form of paroxetine. Extended release. One of the early applications of ion exchange resins in drug formulation is their use in 1 1 extended-release. The first commercial example of this is the Penn- Kinetic system in which dextromethorphan is loaded onto a resin and the resin is then coated. This combination provides an extended-release liquid formulation that is still sold commercially (e.g., Delsym). The technique has also been used for many years for extended-release diclofenac, but without the coating. Until recently, this technology was limited by the release profile. Although the overall release rate could be changed, the shape of the release profile was always the same a typical first-order release. However recent innovations have identified ways to change this shape significantly, even to the point of achieving an almost constant release rate. Abuse liability. During the past few years, there has been much publicity about the abuse of prescription drugs (e.g., OxyContin). Ion exchange resins can be used to make 8 6 4 % Wt gain, 4 hours @4C/75%RH Resin 11% 18% 6% Liquified Sodium Figure 3: The graph shows the results of testing resinates of sodium, a well-known highly deliquescent drug. it more difficult or less desirable to abuse such formulations. The technology can be manipulated to reduce the high associated with intentional abuse, reduce the likelihood of overdose by inadvertent abuse, and make illicit extraction more difficult and less efficient. Multiple benefits The benefits described are not necessarily mutually exclusive to one another. One example is the nicotine chewing gum. In this case, the main reason for making the nicotine resinate (nicotine polacrilex USP) is to extend the release of the nicotine from the chewing gum so that it lasts 1 min. However, the resinate also increases the stability of nicotine and makes it into an easily formulated, less-toxic solid. Another example is Delsym, in which the main reason for the resinate coating is to create an extended-release suspension. However, it also provides excellent taste masking. Finally, the use of a resin to 4 Pharmaceutical Technology EXCIPIENTS & SOLID DOSAGE FORMS 4 www.pharmtech.com

stabilize vitamin B 1 also improves bioavailability. Getting more information Unfortunate for the formulator, ion exchange resin technology related to pharmaceutical formulation is taught in few, if any, schools and cannot be found in many textbooks. Even conducting literature searches through various scientific journals gives only a fragmented description of the technology. The number of manufacturers of pharmaceutical Lansoprazole Conc, mg/l grade resins is also very limited and include Rohm and Haas, Dow Chemical, Purolite, and Ion Exchange India. Listed below are some useful resources to help the formulator find out more about this technology. Textbooks Freidrich Helfferich, Ion Exchange (Dover Publications, Mineola, NY, 1995) Robert Kunin, ed., Ion Exchange Resins (Robert E. Krieger Publishing Co., Huntington, NY, 199) Remington The Science and Practice of Pharmacy,(University of the Sciences, Philadelphia, PA,, th ed.), pp. 93 99. Journal articles/patents Y. Raghunathan, US patent 4,1,778 D.P. Elder et al., Development of a Palatable Liquid Formulation of a Bitter Tasting Drug Using Ion Exchange Resins for Taste Mask- 45 4 35 3 5 15 1 5 Dynamic in vitro dissolution profiles 'as received' Form I Form II Resinate of 'as received' Resinate of Form I Resinate of Form II 1 3 4 5 6 Time, min Figure 4: The graph shows release dissolution test data about lansoprazole and its resinates. ing, Proceedings of Ion Exchange at the Millennium, (Cambridge, UK, 16 1 July ), pp. 36 315 S. Khanna, US patent 4,51,18 W.J. Irwin, R. McHale, and P. J. Watts, Drug Delivery by Ion Exchange Part VII: Release of Acidic Drugs From Anionic Exchange Resinate Complexes, Drug Development and Industrial Pharmacy, 16 (6), 883 898 (199). Web site www.rohmhaas.com/markets/ pharmaceutical.html Conclusion Ion exchange resin excipients should be a part of every formulator s basic toolkit. Although they are not as well-known in the industry as one might expect, ion exchange resin excipients can bring unique benefits and solve some very difficult problems. PT Pharmaceutical Technology EXCIPIENTS & SOLID DOSAGE FORMS 4 5